No Data
No Data
A. G. P. Maintains OrganiGram(OGI.US) With Buy Rating, Raises Target Price to $2.16
Alliance Global Partners Sticks to Its Buy Rating for OrganiGram Holdings (OGI)
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Calendar of Canada Earnings Expected in the Week Ahead
This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations
Cannabis Stock Movers For April 3, 2025